Announce on the Company's resolution for 2021 annual
general shareholders' meeting
Date of events
2022/05/24
To which item it meets
paragraph 18
Statement
1.Date of the shareholders' meeting:2022/05/24
2.Important resolutions I.Profit distribution/deficit compensation:
Report on 2021 earning distribution
3.Important resolutions II.Amendments of the company charter:
Amendment of articles of incorporation
4.Important resolutions III.Business report and financial statements:
Adoption of the 2021 business operation report and financial statements
5.Important resolutions IV.Election for directors and supervisors:NA
6.Important resolutions V.Other matters:
(1)Distribute new shares for capital increase by earnings
(2)Amendment of procedure for lending funds to other party
(3)Amendment of procedure for endorsement and guarantee
(4)Amendment of acquiring and disposing asset
(5)Amendment of procedure for engaging in financial derivative transaction
(6)To discharge the director's non-compete clause
(7)For the Company's subsidiary Bora Health Inc.'s future over the
counter and listing plan, the Company will release the share in
stages and not to participate the future capital increase plan.
7.Any other matters that need to be specified:NA
Attachments
Original Link
Original Document
Permalink
Disclaimer
Bora Pharmaceuticals Co. Ltd. published this content on 24 May 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 24 May 2022 03:47:00 UTC.
Bora Pharmaceuticals Co Ltd is a Taiwan-based company principally engaged in the agency and sales of western medicines, as well as the research, development, manufacture and sales of new drugs and health products. The Company's main products are categorized into prescription drugs and health care products, including central nervous drugs, cardiovascular drugs, antibiotics, antiviral agents, ophthalmic drugs, gastrointestinal drugs, foam ingots and health care products. In addition, the Company has biopharmaceutical technologies related to the development of cell lines for the production of protein drugs, the development and analysis of upstream and downstream processes, as well as the establishment of quality control and testing specifications and the creation of cell banks.
BORA PHARMACEUTICALS CO., LTD. 
